MetaCap

Atea Pharmaceuticals (AVIR) vs Contineum Therapeutics (CTNM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atea Pharmaceuticals (AVIR) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 33.3% versus a loss of 20.7%. Contineum Therapeutics is the larger company by market cap ($340.8 million vs $318.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVIR+33.33%CTNM-20.69%
+114%+36%-42%
Nov 21, 20251 yearNov 20, 2026
AVIR+3.94%CTNM-43.64%
+67%-9%-84%
Apr 1, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVIR versus CTNM key metrics
MetricAVIRCTNM
Share price$3.96$8.68
Market cap$318.00M$340.83M
1-day change+0.76%-3.98%
YTD return+10.92%-24.06%
1-year return+33.33%-20.69%
5-year return-51.35%—
EPS (TTM)$-1.95$-1.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-158.35M$-59.98M
52-week high$6.45$17.79
52-week low$2.96$6.73
Distance from 52-week high-38.60%-51.19%
Analyst consensusbuybuy
Avg. price target upside+127.27%+146.89%
Average volume290.60K776.03K
Shares outstanding80.30M35.35M
Employees5551
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AVIR has outperformed CTNM by 54.0 percentage points over the past year.

About Atea Pharmaceuticals

AVIR stock →

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Contineum Therapeutics

CTNM stock →

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

AVIR vs CTNM FAQ

Which is bigger, Atea Pharmaceuticals or Contineum Therapeutics?

Contineum Therapeutics (CTNM) is larger, with a market capitalization of $340.83M compared with $318.00M for Atea Pharmaceuticals (AVIR).

Which stock has performed better over the past year, AVIR or CTNM?

AVIR returned +33.33% over the past 12 months, compared with -20.69% for CTNM (price return, excluding dividends). Past performance does not predict future results.

Are Atea Pharmaceuticals and Contineum Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons